睿知中国疾病研究地图
候选清单0

正在招募原发性硬化性胆管炎III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

ClinicalTrials.gov 上登记的一项原发性硬化性胆管炎开放试验。牵头方不是本站收录的医院;本站收录的 11 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 11

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心首都医科大学附属北京地坛医院Beijing Ditan Hospital, Capital Medical University北京医院页面
  2. 研究中心首都医科大学附属北京友谊医院Beijing Friendship Hospital北京医院页面
  3. 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
  4. 研究中心广州市第八人民医院(嘉禾院区)Guangzhou Eighth People's Hospital广州医院页面
  5. 研究中心河南省人民医院Henan Provincial People's Hospital郑州医院页面
  6. 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
  7. 研究中心北京大学人民医院Peking University People's Hospital北京医院页面
  8. 研究中心山东大学齐鲁医院Qilu Hospital of Shandong University济南医院页面
  9. 研究中心上海交通大学医学院附属仁济医院Renji Hospital上海医院页面
  10. 研究中心南昌大学第二附属医院Second Affiliated Hospital of Nanchang University南昌医院页面
  11. 研究中心天津医科大学总医院Tianjin Medical University General Hospital天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07387549,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 3

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(3 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Known malignancy or history of malignancy within the last 5 years, with the exception of local, successfully treated basal cell carcinoma or in-situ carcinoma of the uterine cervix.

    排除标准第 7 条

    Participant has or is known to have tested positive for human immunodeficiency virus (HIV) type 1 or 2 at SV.

    排除标准第 18 条

  3. For female participants: known pregnancy, or has a positive serum pregnancy test, or lactating.

    排除标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07387549,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Adults participants aged 18 years or older
  2. Confirmed diagnosis of primary sclerosing cholangitis based on standard clinical, biochemical, and imaging criteria
  3. Compensated liver disease at screening
  4. Stable background therapy, where applicable prior to study entry
  5. Women of childbearing potential have to apply during the entire duration of the study a highly effective method of birth control
  6. Ability to provide written informed consent and comply with study procedures.

排除标准:Exclusion Criteria:

  1. History or presence of other concomitant chronic liver disease
  2. History of hepatic decompensation, including: i) History of liver transplantation, current MELD 3.0 score ≥12 due to hepatic impairment.
  3. Participants with cirrhosis who are also classified as Child-Pugh B or C based on the Child Pugh score.
  4. History of biliary intervention within 60 days prior to the screening period, and/or presence of percutaneous drain or bile duct stent at SV.
  5. History of bacterial cholangitis, and/or participant on antibiotics for prophylaxis of recurrent cholangitis within 60 days prior to the SV.
  6. History or any current suspicion of cholangiocarcinoma or hepatocellular carcinoma
  7. Known malignancy or history of malignancy within the last 5 years, with the exception of local, successfully treated basal cell carcinoma or in-situ carcinoma of the uterine cervix.
  8. Medical conditions that may cause non-hepatic increases in ALP (e.g. Paget's disease).
  9. Administration of the following medications are prohibited as specified below:
  10. Participants who are currently participating in, plan to participate in, or have participated in an investigational drug or medical device study containing active substance within 30 days or five half-lives, whichever is longer, prior to the SV. - Participants with previous exposure to elafibranor.
  11. Electrocardiogram (ECG) with QT interval corrected by Fridericia's formula (QTcF) >450 msec in males or QTcF >470 msec in females for participants without bundle branch block.
  12. Significant renal disease,
  13. For female participants: known pregnancy, or has a positive serum pregnancy test, or lactating.
  14. Regular alcohol intake in excess of the recommended limit of 2 standard drinks per day for men or 1 standard drink per day for women
  15. History of alcohol abuse, or other substance abuse within 1 year prior to SV.
  16. Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that contraindicates participation in the study.
  17. Mental instability or incompetence
  18. Participant has or is known to have tested positive for human immunodeficiency virus (HIV) type 1 or 2 at SV.
  19. Medical conditions that may diminish life expectancy to <2 years.

引自 ClinicalTrials.gov, NCT07387549, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07387549,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07387549